Colleen, apologies if you've addressed this elsewhere, but are past meetings available for viewing online; I missed several bc I had the wrong access address?
And, would it be appropriate to have Dr. Kwon at the outset note if his talk *would/could or not also apply* to denovo patients with or without metastases? (To explain, I, and I expect others as well, sometimes wonder if such distinctions imply an impossible extension to other categories of patients.)
Thanks.